Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Dentomaxillofac Radiol ; 49(4): 20190392, 2020 May 01.
Article in English | MEDLINE | ID: mdl-31794257

ABSTRACT

OBJECTIVES: To assess patients with and without temporomandibular disorders (TMD) infrared thermography according to the differences in thermal radiance using quantitative sensitivity and specificity tests; and to evaluate the thermal asymmetry and the correlation of the thermal intensity with the intensity of pain upon palpation. METHODS: This cross-sectional study performed a quantitative evaluation of clinical and thermographic examinations. The volunteers were evaluated for the presence of TMD using RDC/TMD (Diagnostic Research Criteria for Temporomandibular Disorders), and were divided into two groups: TMD group (n = 45); control group (n = 41), composed of volunteers without TMD, according to the Fonseca Anamnestic Index. The images were assessed for selected regions of interest for the masseter, anterior temporal and TMJ muscles. The mean values ​​of the areas of both groups were compared under the receiver operating characteristic curve. Spearman correlation analysis (non-parametric data) between pain level and mean temperature, by region, and the Pearson's χ2 test was used to verify the association between the presence of temperature and pain asymmetry. The level of significance was set at p < 0.05. RESULTS: Both Groups, with and without TMD, presented with absolute and non-dimensional mean temperature without statistical differences (p>0.05). When correlating temperature with intensity of pain upon palpation, a negative correlation was observed for the masseter muscle. CONCLUSION: Infrared Thermography resulted in low area under the curve, making it difficult to differentiate TMD via thermographic analysis. The intensity of pain upon palpation in patients with TMD may be accompanied by a decrease in local temperature.


Subject(s)
Temporomandibular Joint Disorders/diagnostic imaging , Thermography , Cross-Sectional Studies , Humans , Masseter Muscle/diagnostic imaging , Sensitivity and Specificity , Temporomandibular Joint/diagnostic imaging
2.
Ultrason Sonochem ; 48: 340-348, 2018 Nov.
Article in English | MEDLINE | ID: mdl-30080559

ABSTRACT

TiO2 is a common inorganic filter used in sunscreens due to its photoprotective effect on the skin against UV radiation. However, the use of this kind of material in cosmetics is limited by its inherent photocatalytic activity. It is known that coating on TiO2 surface can improve some features. Although, many of the methodologies used for this purpose are still laborious and time-consuming. Thus, this work reports a novel, easy, cheap and fast strategy to coat TiO2 particles by using a sonochemistry approach, aiming to decrease photocatalytic activity and to enhance colloidal stability. For this proposal, SiO2, Al2O3, ZrO2 and sodium polyacrylate (PAANa) were used to tune the surface of commercial TiO2 particles and they were applied in a sunscreen formulation. The samples were characterized by XRPD, FT-IR, DLS, EDS, SEM and TEM. The photocatalytic activity and UV-shielding ability were also evaluated. The sunscreen formulations were prepared and characterized by zeta potential, DLS, and Sun Protection Factor (SPF). FT-IR, EDS, and charge surface of the particles confirmed the success of the sonochemistry coating. Additionally, TiO2@Al2O3, TiO2@SiO2 and TiO2@PAANa show a lower photocatalytic activity than original TiO2 with similar UV-shielding ability. The sunscreens produced with the coated TiO2 have similar SPF to the one with commercial TiO2. Specifically, the sunscreen with TiO2@PAANa shows an increase in colloidal stability. Herein, the incorporation of the sonochemical-coated TiO2 particles in sunscreen formulations may produce sunscreens with better aesthetic appearance and a greater health security due to its lower free radicals production.

3.
Exp Clin Endocrinol Diabetes ; 122(9): 553-7, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24918529

ABSTRACT

BACKGROUND: In non-PCOS patients the concentration of glycated hemoglobin (HbA1C) has been employed to identify individuals at higher risk for impaired glucose tolerance (IGT) and diabetes mellitus. A few studies have examined the role of HbA1C in PCOS patients and current results are controversial. AIM: To compare the strength of the association between glycated hemoglobin and other predictors of cardiovascular risk in polycystic ovary syndrome (PCOS). METHODS: This cross-sectional study enrolled 197 PCOS patients and 72 non-PCOS women. Transvaginal ultrasound, biochemical and hormone measurement were performed. Glycated hemoglobin (HbA1C) was correlated with other variables related to dysmetabolic/vascular diseases. RESULTS: The HbA1C levels were 6.0±1.4% and 4.9±0.4% in PCOS patients and non-PCOS controls, respectively (p<0.001). The HbA1C levels were≥5.7% in 46.4% of PCOS and in none of the control subjects (OR=90.8). HbA1C was well-correlated with several anthropometric, metabolic and endocrine parameters. Stepwise multiple regression including HbA1C and other known predictors of cardiovascular risk resulted in a significant model in which body mass index (BMI) and free testosterone exhibited the best correlation with HbA1C (adjusted R(2)=0.530; F=39.8; p<0.001). CONCLUSION: HbA1C was elevated and correlated with anthropometric, biochemical and endocrine variables of metabolic/vascular disease risks in PCOS patients. Combined HbA1C, BMI and free testosterone levels provided a significant model with potential use to evaluate metabolic/vascular disease in PCOS patients.


Subject(s)
Glycated Hemoglobin/metabolism , Polycystic Ovary Syndrome/blood , Polycystic Ovary Syndrome/complications , Vascular Diseases/blood , Vascular Diseases/etiology , Adult , Body Mass Index , Cross-Over Studies , Female , Humans , Risk Factors , Testosterone/blood
4.
Ecotoxicol Environ Saf ; 73(3): 320-5, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19910047

ABSTRACT

The aim of this study was to access the genotoxic potential of Extremoz Lake waters in Northeastern Brazilian coast, using the Allium cepa system, piscine micronucleus test and comet assay. In addition, heavy metal levels were quantified by atomic absorption flame spectrometry. The results of the A. cepa system showed significant changes in the frequency of chromosome aberrations and in the mitotic index compared to negative control. No significant changes were observed in micronuclei frequency in the erythrocytes of Oreochromis niloticus. The comet assay showed a statistically significant alteration in the level of DNA breaks of O. niloticus. Chemical analysis detected an increase in heavy metal levels in different sampling periods. These results point out a state of deterioration of water quality at Extremoz Lake, caused by heavy metal contamination and genotoxic activity. It is recommended to establish a monitoring program for the presence of genotoxic agents in this water lake.


Subject(s)
Environmental Monitoring , Metals, Heavy/toxicity , Mutagens/toxicity , Water Pollutants, Chemical/toxicity , Water Pollution/analysis , Animals , Chromosome Aberrations/chemically induced , Comet Assay , DNA Damage , Fishes , Fresh Water/chemistry , Metals, Heavy/classification , Micronuclei, Chromosome-Defective/chemically induced , Micronucleus Tests , Mitosis/drug effects , Mitotic Index , Mutagens/classification , Onions/drug effects , Onions/genetics , Spectrophotometry, Atomic , Water Pollutants, Chemical/classification
5.
Nanoscale Res Lett ; 4(10): 1247-1253, 2009 Jul 16.
Article in English | MEDLINE | ID: mdl-20596391

ABSTRACT

Electrostatic self-assembly was used to fabricate new smart multi-layer coatings, using a recombinant elastin-like polymer (ELP) and chitosan as the counterion macromolecule. The ELP was bioproduced, purified and its purity and expected molecular weight were assessed. Aggregate size measurements, obtained by light scattering of dissolved ELP, were performed as a function of temperature and pH to assess the smart properties of the polymer. The build-up of multi-layered films containing ELP and chitosan, using a layer-by-layer methodology, was followed by quartz-crystal microbalance with dissipation monitoring. Atomic force microscopy analysis permitted to demonstrate that the topography of the multi-layered films could respond to temperature. This work opens new possibilities for the use of ELPs in the fabrication of biodegradable smart coatings and films, offering new platforms in biotechnology and in the biomedical area.

6.
Cephalalgia ; 22(4): 309-12, 2002 May.
Article in English | MEDLINE | ID: mdl-12100094

ABSTRACT

Rizatriptan is an effective and fast acting drug for the acute treatment of migraine. As with any other acute treatment for migraine, headache recurrence may occur in up to one-third of responders. Combination with non-steroidal anti-inflammatory drugs (NSAIDs) seems to reduce the incidence of headache recurrence in clinical practice. Rofecoxib is a member of a new class of NSAIDs, which selectively inhibits the COX-2 enzyme and therefore is associated with a lower risk of gastrointestinal side-effects; the drug has a long plasma half-life (17 h). This open label study compared rizatriptan with rizatriptan plus rofecoxib in the acute treatment of migraine. Fifty-six triptan naive patients from a tertiary centre (37 women and 19 men, ages 16-55 years, mean 35 years) with International Headache Society migraine were randomized into two groups. They were instructed to treat three consecutive moderate or severe attacks with either 10 mg rizatriptan (group 1: 18 women and 10 men) or with 10 mg rizatriptan plus 25 mg rofecoxib (group 2: 19 women and 9 men). The presence of headache and nausea at 1, 2 and 4 h, and of side-effects, use of rescue medication and recurrence were compared. Fifty-four patients completed the study. Group 1 treated 76 attacks and group 2 treated 81 attacks. Absence of headache at 1 h was seen in 19 attacks (25%) in group 1 and in 34 attacks (42%) in group 2 (P=0.082); at 2 h absence of headache was seen in 60% of group 1 attacks and in 76% of group 2 attacks (P=0.115). At 4 h, 75% of group 1 attacks and 88% of group 2 attacks were pain free (P=0.122). With regard to nausea, of those who had nausea at baseline, 31% and 49% of attacks in groups 1 and 2, respectively, were nausea free at 1 h (P=0.091), 75% and 79% at 2 h (P=0.736) and 82% and 91% (P=0.479) at 4 h. Recurrence, based on all attacks of those patients who achieved pain free at 4 h, was observed in 53% of group 1 and 20% of group 2 attacks (P<0.001). Sustained pain-free rates (for the 4-h time point) were 45.6% of group 1 and 78.9% of group 2 attacks. There were no significant differences with regard to rescue medication consumption after 4 h and side-effects in both groups. There was a non-significant trend for the combination group to have a higher response rate. The group treated with rizatriptan and rofecoxib had a lower recurrence rate than the group treated with rizatriptan. This study demonstrated that combining a fast acting triptan such as rizatriptan with rofecoxib reduced headache recurrence rates, was well tolerated and may be more effective than the use of rizatriptan alone. Double-blind, placebo-controlled studies are necessary to confirm these observations.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Cyclooxygenase Inhibitors/therapeutic use , Lactones/therapeutic use , Migraine Disorders/drug therapy , Serotonin Receptor Agonists/therapeutic use , Triazoles/therapeutic use , Adolescent , Adult , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Cyclooxygenase Inhibitors/administration & dosage , Drug Therapy, Combination , Female , Humans , Lactones/administration & dosage , Male , Middle Aged , Migraine Disorders/complications , Migraine Disorders/prevention & control , Nausea/drug therapy , Nausea/etiology , Pilot Projects , Prospective Studies , Recurrence , Serotonin Receptor Agonists/administration & dosage , Sulfones , Triazoles/administration & dosage , Tryptamines
7.
Arq Neuropsiquiatr ; 59(3-B): 708-11, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11593269

ABSTRACT

BACKGROUND AND OBJECTIVES: Triptans are effective drugs for the acute treatment of migraine. However, 30-40% of the patients commonly present recurrence before 24 hours therefore requiring another dose. Nonsteroidal anti-inflammatory drugs (NSAID) such as tolfenamic acid and naproxen sodium combined with sumatriptan have demonstrated efficacy in reducing recurrence observed with the single use of this drug. Steroids also have been suggested to treat refractory migraine and status migranosus. The aim of this study was to evaluate whether patients presenting frequent recurrence with the combination triptan plus NSAID, would decrease it with the association of dexamethasone. METHOD: Twenty three patients, 17 women and 6 men with migraine according to IHS criteria were prospectively studied. All patients presented frequent recurrence (> or= 60%, mean recurrence rate 74,8%) with the single use of sumatritpan 100 mg or zolmitriptan 2,5 mg or rizatriptan 10mg in at least 5 consecutive attacks, and didn't present a reduction of the recurrence rate superior than 20% with the combination of tolfenamic acid 200 mg or rofecoxib 25 mg in at least 5 other consecutive attacks (mean recurrence rate 60%). The patients had to treat 6 consecutive moderate or severe migraine attacks with their usual combination plus 4 mg of dexamathasone with a maximum of twice a week, and fill out a diary reporting headache parameters. RESULTS: Twenty patients, 16 women and 4 men completed the study. Of those who completed the study, 11 took rizatriptan plus rofecoxib, 4 rizatriptan plus tolfenamic acid, 3 zolmitriptan plus rofecoxib, 1 zolmitriptan plus tolfenamic acid and 1 patient took sumatriptan plus tolfenamic acid, having the 20 patients taken as a third medication, a single tablet of 4 mg of dexamethasone. All patients took oral formulations and none presented vomiting after that. Among all 20 patients, one female and one male patient presented recurrence in 3 out of the 6 attacks (50%) while the remaining 18 patients revealed recurrence in 1 or 2 treated attacks (mean 23,4%) (p<0,001). CONCLUSION: We concluded that the judicious use of oral dexamethasone might be useful for a limited population of migraine patients still presenting recurrence with the combination of a triptan and a NSAID. Case-control studies and studies with a randomized double-blind design are necessary to confirm these observations.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Dexamethasone/therapeutic use , Migraine Disorders/drug therapy , Serotonin Receptor Agonists/therapeutic use , Sumatriptan/therapeutic use , Adolescent , Adult , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Naproxen/therapeutic use , Prospective Studies , Secondary Prevention , ortho-Aminobenzoates/therapeutic use
8.
Arq Neuropsiquiatr ; 59(1): 46-9, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11299430

ABSTRACT

Several oral nonsteroidal anti-inflammatory drugs (NSAIDs) are effective to treat migraine attacks. Lysine clonixinate (LC) is a NSAID derived from nicotinic acid that has proven to be effective in various pain syndromes such as renal colic and muscular pain. The aim of this double-blind, placebo-controlled study was to evaluate the efficacy of oral LC compared to placebo in the acute treatment of migraine. Sixty four patients with the diagnosis of migraine, according to the IHS criteria, were studied prospectively. Patients received LC or placebo once the headache reached moderate or severe intensity for 6 consecutive attacks. With regard to the moderate attacks, LC was superior than placebo after 1, 2 and 4 hours. The consumption of other rescue medications after 4 hours was significantly higher in the placebo group. With regard to the severe attacks, there was no difference between the active drug group and the placebo group concerning headache intensity and consumption of other rescue medications. We conclude that the NSAID lysine clonixinate is effective in treating moderately severe migraine attacks. It is not superior than placebo in treating severe migraine attacks.


Subject(s)
Analgesics/administration & dosage , Clonixin/analogs & derivatives , Clonixin/administration & dosage , Lysine/analogs & derivatives , Lysine/administration & dosage , Migraine Disorders/drug therapy , Administration, Oral , Adolescent , Adult , Double-Blind Method , Female , Humans , Male , Middle Aged , Prospective Studies
9.
Cephalalgia ; 20(2): 107-13, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10961766

ABSTRACT

The majority of the patients who seek medical care in tertiary headache centres present with transformed migraine, and convert to daily headache, as a result of excessive intake of symptomatic medications (SM). This study aimed to analyse the possibility of using a short course of oral prednisone for detoxifying patients with chronic daily headache due to medication overuse in an out-patient setting. Four hundred patients with headache occurring more than 28 days per month for longer than 6 months were studied (mean baseline frequency of 0.96). Symptomatic medications were stopped suddenly and prednisone was initiated in tapering doses during 6 days, followed by the introduction of preventive treatment. Withdrawal symptoms and the frequency, intensity and duration of the headache, as well as the consumption of rescue medications, were analysed during the first 16 and 30 days of withdrawal. Eighty-five percent of the patients experienced a reduction in headache frequency and no patients presented severe attacks during the first 6 days. With regard to the following 10 days, 46% of the patients experienced at least 2 days without headache and 58% less intense attacks. Most of the patients noticed attacks with longer duration. After the 30-day period there was a significant decrease in headache frequency (mean 0.83, P<0.001), and no patients returned to overuse of SM. This study demonstrates that it is possible to detoxify patients suffering from rebound headaches, using oral prednisone during the first days of withdrawal, in an out-patient setting.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Headache/drug therapy , Migraine Disorders/drug therapy , Prednisone/therapeutic use , Substance Withdrawal Syndrome/drug therapy , Adult , Analgesics/adverse effects , Anti-Inflammatory Agents/pharmacology , Emotions/drug effects , Female , Headache/chemically induced , Headache/psychology , Humans , Male , Middle Aged , Migraine Disorders/psychology , Prednisone/pharmacology , Prospective Studies , Sleep Disorders, Intrinsic/drug therapy , Sleep Disorders, Intrinsic/psychology , Substance Withdrawal Syndrome/psychology
10.
Arq Neuropsiquiatr ; 57(4): 990-3, 1999 Dec.
Article in Portuguese | MEDLINE | ID: mdl-10683691

ABSTRACT

Most daily headache patients seen in specialized clinics present a past history of migraine. Some authors refer to it as transformed migraine and emphasize its milder intensity and clinical characteristics different from migraine. The aim of this study was to evaluate the clinical presentation of the daily headache in patients with prior history of migraine. We studied retrospectively 215 patients. We observed that a significant percentage of the patients presenting the so-called transformed migraine, reported frontal and/or temporal bilateral pain and had pressure or tightening pain, which is a characteristic of chronic tension-type headache. It emphasizes the loss or changing of the standard migraine features. The pulsatile pain quality remained as an important feature, specially for those with intermittent typical migraine attacks.


Subject(s)
Headache/diagnosis , Migraine Disorders/diagnosis , Adolescent , Adult , Aged , Child , Female , Humans , Male , Middle Aged , Migraine Disorders/complications , Migraine Disorders/epidemiology , Retrospective Studies
13.
Rev. bras. anestesiol ; 33(5): 389-91, 1983.
Article in Portuguese | LILACS | ID: lil-17153

ABSTRACT

Descrevemos nesse artigo a organizacao funcional de um sistema ambulatorial, visando atendimento multiespecializado de pacientes com quadros de dor cronica, enfatizando o papel exercido pelo anestesiologista


Subject(s)
Humans , Ambulatory Care , Anesthesiology , Pain
14.
Rev. bras. anestesiol ; 32(4): 295-8, 1982.
Article in Portuguese | LILACS | ID: lil-10178

ABSTRACT

A participacao do anestesiologista no conhecimento da problematica do paciente cirurgico tem sido nossa preocupacao constante. Desde julho de 1978, criou-se a reavaliacao conjunta dos pacientes cirurgicos, na semana anterior a data prevista da cirurgia, da qual participam anestesiologistas, cirurgioes e colegas consultores Os pacientes sao entrevistados pelos anestesiologistas, seus prontuarios sao revistos, faz-se um exame clinico dirigido e discutem-se os problemas pertinentes com os cirurgioes ou consultores e os pacientes recebem a orientacao final. De 866 pacientes que foram vistos, 49 pacientes foram medicados, para reavaliacao na internacao. 36 cirurgias foram suspensas pelos anestesiologistas, por apresentarem diversas patologias. Dois pacientes foram internados para tratamento clinico hospitalar. Esta experiencia trouxe diversas contribuicoes: uma melhor avaliacao dos pacientes, evitou-se a marcacao de cirurgia sem adequado preparo; racionalizando-se o uso do centro cirurgico, melhora-se a possibilidade da aceitacao das tecnicas regionais em pacientes pediatricos e melhora-se tambem o relacionamento cirurgiao -anestesiologista, contribuindo para a unidade de pensamento e de conduta dos proprios anestesiologistas


Subject(s)
Humans , Preanesthetic Medication
SELECTION OF CITATIONS
SEARCH DETAIL
...